Biofourmis Raises $300 million Series D

Biofourmis has raised $300M in Series D funding led by General Atlantic. Predicting patient deterioration 6 hours before clinical signs saves lives. The funds will be used to Scale AI hospital-at-home program and expand to post-surgical monitoring.

What it does

Predicting patient deterioration 6 hours before clinical signs saves lives.

Traction

Artificial Intelligence (AI) in Remote Patient Monitoring Market Size, 2034 The company is using its latest financing to scale, with the Series D round serving as the clearest current traction signal in the source bundle.

Trend impact

Predicting patient deterioration 6 hours before clinical signs saves lives. As adoption in Healthcare & Life Sciences expands, focused products from Biofourmis can pressure incumbents or broader platforms that do not address the same problem directly.

Funding history

• May 1, 2021 · Series D · $300 million · General Atlantic

Products & services

• Artificial Intelligence capability
• Remote Patient Monitoring Market Size, 2034 - Fortune Business Insights capability
• Grand View Research. Wearable Cardiac Devices Market Size Report, 2026- capability
• Grand View Research capability
• Grand View Research Projecting the Global Artificial Intelligence capability